Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Mk 1454 (Primary) ; Pembrolizumab (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 02 Apr 2018 Planned number of patients changed from 80 to 97.
- 14 Mar 2018 According to a Merck & Co media release, results from the study will be present at the American Association for Cancer Research (AACR) Annual Meeting 2018.
- 06 Feb 2018 Planned End Date changed from 22 Oct 2020 to 22 Oct 2021.